Ipilimumab
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 6729 publications
Immunotherapy Response in Microsatellite Instability-High Gastroesophageal Adenocarcinoma.
Journal: JAMA surgery
Published: April 15, 2026
A plain language summary of the CheckMate 9DW study: nivolumab in combination with ipilimumab for unresectable hepatocellular carcinoma (advanced liver cancer).
Journal: Future oncology (London, England)
Published: April 15, 2026
Update on pleural mesothelioma.
Journal: Current opinion in pulmonary medicine
Published: April 15, 2026
Effectiveness and safety of first-line nivolumab-ipilimumab in metastatic renal cell carcinoma.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 13, 2026
Comparative pharmacovigilance signals for PD-1, PD-L1, CTLA-4, and LAG-3 immune checkpoint inhibitor-associated hemophagocytic lymphohistiocytosis in the FAERS database.
Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Published: April 13, 2026
Distribution of Immune Cells in Tumor Microenvironment Correlates With Checkpoint Inhibitor Response in Nasopharyngeal Carcinoma: A Multiregional Study.
Journal: JCO global oncology
Published: April 10, 2026
Efficacy of Ipilimumab and Nivolumab Rechallenge in a Long-Term Melanoma Survivor: A Case Report.
Journal: The American journal of case reports
Published: April 09, 2026
Correction: Comparison of real-world efficacy and safety of nivolumab plus ipilimumab or pembrolizumab combined with platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer in a German population.
Journal: Cancer immunology, immunotherapy : CII
Published: April 06, 2026
Narcolepsy type 1 following immune checkpoint inhibitor therapy for metastatic melanoma.
Journal: BMJ case reports
Published: April 06, 2026
Caffeine as a Viscosity-Reducing Agent for High-Concentration mAb Formulations: Insights from Molecular Dynamics Simulations.
Journal: The journal of physical chemistry. B
Published: April 03, 2026
Therapeutic targeting of PD-1/PD-L1 and CTLA-4 in colorectal cancer: tumor-intrinsic and immune checkpoint signaling.
Journal: Expert opinion on biological therapy
Published: April 02, 2026
Last Updated: 04/28/2026